Biocon informs about disclosure

24 Mar 2025 Evaluate
Biocon has informed that Biocon Pharma, a wholly owned subsidiary of the Company, has received approval from the U.S Food and Drug Administration (U.S. FDA) for its ANDA Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) single-dose vial. Norepinephrine bitartrate injection is indicated to raise blood pressure in adult patients with acute hypotension. The approval further adds to Biocon’s portfolio of complex drug products. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.


Biocon Share Price

312.00 -14.40 (-4.41%)
25-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.85
Dr. Reddys Lab 1173.55
Cipla 1525.50
Lupin 2018.35
Zydus Lifesciences 859.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...